264 The outcomes of the currently ongoing FLOW study will further inform the therapeutic potential of GLP-1R analogues to improve renal and cardiovascular prognosis in patients with renal impairment and T2D
It falls under the drug classes of antidiabetics and GLP-1 agonists
An established delivery platform would ensure that the next wave of SARS-CoV-2 infections and other emerging viruses, potentially including novel betacoronaviruses, are met with a more efficient and rapid response
This is a synbiotic, which means it includes prebiotics to enhance the effectiveness of the probiotics
I used to try and get obesity researchers, I once proposed this to a guy named Keith Frane at the University of, I forget if it's Cambridge or Oxford, I think it was Oxford
Patients should also inform their healthcare provider if gastrointestinal symptoms significantly impair quality of life or adherence to treatment